NYSE:NVRO - Nevro Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$64.11 -0.35 (-0.54 %)
(As of 04/24/2019 04:47 AM ET)
Previous Close$64.46
Today's Range$63.27 - $65.20
52-Week Range$34.75 - $94.34
Volume496,982 shs
Average Volume709,573 shs
Market Capitalization$1.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.21
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.

Receive NVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone650-251-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$387.29 million
Book Value$8.14 per share

Profitability

Net Income$-49,210,000.00

Miscellaneous

Employees804
Market Cap$1.95 billion
Next Earnings Date5/6/2019 (Estimated)
OptionableOptionable

Nevro (NYSE:NVRO) Frequently Asked Questions

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

How were Nevro's earnings last quarter?

Nevro Corp (NYSE:NVRO) released its earnings results on Thursday, February, 21st. The medical equipment provider reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.15. The medical equipment provider had revenue of $107.90 million for the quarter, compared to the consensus estimate of $107.39 million. Nevro had a negative return on equity of 20.13% and a negative net margin of 12.70%. The business's revenue was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.15) EPS. View Nevro's Earnings History.

When is Nevro's next earnings date?

Nevro is scheduled to release their next quarterly earnings announcement on Monday, May 6th 2019. View Earnings Estimates for Nevro.

What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its FY 2019 earnings guidance on Thursday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $400-410 million, compared to the consensus revenue estimate of $419.3 million.

What price target have analysts set for NVRO?

11 brokers have issued 12-month price targets for Nevro's stock. Their predictions range from $35.00 to $105.00. On average, they anticipate Nevro's stock price to reach $64.6364 in the next twelve months. This suggests a possible upside of 0.8% from the stock's current price. View Analyst Price Targets for Nevro.

What is the consensus analysts' recommendation for Nevro?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 2 sell ratings, 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nevro.

What are Wall Street analysts saying about Nevro stock?

Here are some recent quotes from research analysts about Nevro stock:
  • 1. According to Zacks Investment Research, "Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California. " (2/27/2019)
  • 2. Northland Securities analysts commented, "We are introducing our FY20 numbers, and our rating / PT remains the same." (1/11/2019)

Has Nevro been receiving favorable news coverage?

Headlines about NVRO stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Nevro earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of Nevro's key competitors?

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), Micron Technology (MU), NVIDIA (NVDA), Celgene (CELG), AbbVie (ABBV), Ctrip.Com International (CTRP), Gilead Sciences (GILD), Incyte (INCY), Starbucks (SBUX) and ABIOMED (ABMD).

Who are Nevro's key executives?

Nevro's management team includes the folowing people:
  • Mr. Andrew H. Galligan, Chief Financial Officer (Age 63)
  • Mr. Patrick Schmitz, VP of Operations (Age 59)
  • Mr. Doug Alleavitch, VP of Quality (Age 58)
  • Mr. D. Keith Grossman, Pres, CEO & Director (Age 59)
  • Ms. Juliet Cunningham, VP of Investor Relations

How do I buy shares of Nevro?

Shares of NVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $64.11.

How big of a company is Nevro?

Nevro has a market capitalization of $1.95 billion and generates $387.29 million in revenue each year. The medical equipment provider earns $-49,210,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Nevro employs 804 workers across the globe.

What is Nevro's official website?

The official website for Nevro is http://www.nevro.com.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The medical equipment provider can be reached via phone at 650-251-0005 or via email at [email protected]


MarketBeat Community Rating for Nevro (NYSE NVRO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  362 (Vote Outperform)
Underperform Votes:  241 (Vote Underperform)
Total Votes:  603
MarketBeat's community ratings are surveys of what our community members think about Nevro and other stocks. Vote "Outperform" if you believe NVRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel